Herpes Simplex Virus (HSV-2) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although most individuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotional and physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at the public health level extremely challenging.
Vaccine manufacturers have pursued the development of both prophylatic (PX) and therapeutic (TX) HSV vaccines. Notably, GSK's Simplirix (gD) in Phase III studies showed efficacy against acquisition of GH disease only in double seronegative women. It was not effective in males nor women already infected with HSV-1, the major cause of oral herpes or "cold sores". Although further trials are testing Simplirix (HerpeVac Study) - there are now important questions of how a HSV vaccine would be deployed and indeed, how manufacturers can develop second generation improved products.
This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for a putative HSV-2 vaccine until 2035. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on new adolescent vaccines.
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 17.5%.
Please review the TERMS and CONDITIONS of purchase.
